Real-World Study Reveals Treatment Gap in IDH-Mutant Glioma, Supporting Need for Early Intervention
Key Insights
Real-world data from 5,894 patients with IDH-mutant glioma (search) shows substantial proportions managed with observation alone, highlighting an unmet need for effective early intervention.
Among patients with grade 2 gliomas, 53% remained on observation at 90 days post-surgery, with 43% still under observation after 5 years.
Vorasidenib (Vorangio (search)), approved by FDA in August 2024, offers a low-toxicity treatment option that could address this gap in early intervention for IDH-mutant gliomas.
A comprehensive real-world analysis of nearly 6,000 patients with IDH-mutant glioma (search) has revealed significant treatment gaps that underscore the need for effective early intervention options in this patient population. The findings, presented at the 2025 Society for Neuro-Oncology (search) Annual Meeting, demonstrate that a substantial proportion of patients are managed with observation alone, creating an opportunity for newly approved targeted therapies.
Study Reveals Widespread Use of Observation Strategy
The retrospective analysis examined 5,894 patients aged 12 years and older with IDH-mutant glioma (search), revealing distinct treatment patterns based on tumor grade and patient age. Of the total cohort, 3,212 patients (54%) had grade 2 tumors while 2,682 patients (46%) had grade 3 tumors, with a median age at diagnosis of 39 years.
Following initial surgery, 2,058 patients were placed on observation while 3,660 initiated active therapies within 90 days. Among those initially observed, 1,568 remained on observation until the study's end in 2022, while 490 eventually received chemotherapy or radiation after an initial observation period.
Age and Grade Influence Treatment Decisions
The data revealed significant differences in treatment initiation based on patient demographics and tumor characteristics. By 90 days post-surgery, 70% of patients aged 40 years or older had initiated therapy, compared with 57% of those aged 12 to 39 years. Conversely, 43% of younger patients and 30% of older patients remained on observation at 90 days, with 34% and approximately 22%, respectively, still under observation after 5 years.
Tumor grade also significantly influenced treatment patterns. Among patients with grade 2 gliomas, 47% had initiated therapy by 90 days post-surgery, while 82% of those with grade 3 gliomas received active treatment within the same timeframe. At 90 days, 53% of grade 2 patients and 18% of grade 3 patients remained on observation, with 43% and 10%, respectively, still under observation after 5 years.
Identifying Unmet Medical Needs
"Historical management patterns show that a substantial proportion of patients with [IDH]-mutated glioma were managed with observation, suggesting an unmet need for an effective early intervention," researchers concluded in their poster presentation. "While younger patients (aged 12 to 39 years) and those with World Health Organization (WHO) grade 2 glioma were more likely to undergo observation, a substantial proportion of patients aged [at least] 40 years and those with WHO grade 3 glioma also underwent observation."
The researchers emphasized that the use of radiation or chemotherapy in older patients and those with grade 3 gliomas, given these treatments' well-established long-term adverse effects, highlights the critical need for less-toxic alternative treatment options.
Vorasidenib Addresses Treatment Gap
Vorasidenib (Vorangio (search)) represents a potential solution to this treatment gap. The researchers noted that vorasidenib "offers an early, effective, low-toxicity treatment option across these patient groups." The drug received FDA approval in August 2024 for treating adult and pediatric patients at least 12 years old with grade 2 astrocytoma (search) or oligodendroglioma (search) harboring susceptible IDH1 (search) or IDH2 (search) mutations following surgery, including biopsy, sub-total resection, or gross total resection.
As an IDH1 (search) and IDH2 (search) inhibitor, vorasidenib became the first systemic therapy approved by the FDA specifically for patients with grade 2 astrocytoma (search) or oligodendroglioma (search) with susceptible IDH1 or IDH2 mutations.
Long-term Efficacy Data Supports Clinical Benefit
Recent long-term results from the phase 3 INDIGO trial, published in The Lancet Oncology, demonstrate vorasidenib's sustained clinical benefit. At a median follow-up of 20.1 months, patients treated with vorasidenib experienced superior progression-free survival compared to those receiving placebo, with disease progression occurring in 32% of patients who received the drug versus 64% of those who did not.
These findings provide compelling evidence that vorasidenib could transform the treatment landscape for patients with IDH-mutant gliomas, offering an effective alternative to the watch-and-wait approach that has historically dominated management of these slow-growing tumors.